Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma

SIMPLE SUMMARY: Malignant pleural mesothelioma (MPM) is an aggressive cancer linked to asbestos exposure with an extremely poor outcome. Despite the recent approval of immune checkpoint blockade-based therapies, MPM still remains a fatal cancer that challenges physicians and scientists. Enhancer of...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Khatib, MHD Ouis, Pinton, Giulia, Moro, Laura, Porta, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000483/
https://www.ncbi.nlm.nih.gov/pubmed/36900330
http://dx.doi.org/10.3390/cancers15051537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000483/
https://www.ncbi.nlm.nih.gov/pubmed/36900330
http://dx.doi.org/10.3390/cancers15051537

Ejemplares similares